Organon & Co | OGN - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Celltrion KRW 16.7T 182.36B 2025-09
Cspc Pharmaceutical CNY 33.18B 71.46M 2025-12
Deva Holding AS TRY 5.79B 604.07M 2023-09
Dianthus Therapeutics USD 493.4M 53.05M 2025-12
Divis Laboratories Ltd INR 154.13B 4.44B 2025-09
Gilead Sciences USD 22.62B 1.16B 2025-12
Glaxosmithkline GBP 22.06B 360M 2025-12
Kangmei Pharma CNY 7.22B 504.3M 2025-09
Knight Therapeutics CAD 767.27M 480K 2025-12
Laboratorios Farma EUR 539.39M 22.74M 2023-12
Malin Corporation EUR 193.2M 75M 2024-12
Medical Developments International AUD 54.77M 335K 2025-12
Merck USD 51.85B 2.79B 2025-09
Neuren Pharmaceuticals AUD 338.45M 15.18M 2025-12
Novartis USD 46.13B 1.8B 2025-12
Organigram Holdings CAD 369.46M 20.33M 2025-12
Organon & Co USD 906M 173M 2025-09
Ovoca Bio EUR 1.26M 7.41M 2025-06
Pharma Mar EUR 251.83M 54.32M 2025-12
Qiagen NV USD 3.78B 128.73M 2025-12
Sartorius EUR 2.67B 9.9M 2025-09
Sino Biopharmaceutical CNY 34B 1.48B 2025-06
Tilray USD 1.58B 39.08M 2025-09
Zealand Pharma A/S 14.83B 331.99M 2025-12